Clinical Trial Update: Neoadjuvant Chemotherapy of Nanoparticle Albumin-bound Paclitaxel in Squamous Cell Carcinoma of Esophagus [Phase 2]

View source ↗

Summary

A Phase 2 trial of nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy for esophageal squamous cell carcinoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Squamous Cell Carcinoma

Drugs mentioned

• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: Zhejiang University | Conditions: Squamous Cell Carcinoma of Esophagus | Phase 2 | Status: WITHDRAWN